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Development of osteoporosis severely complicates
long-term glucocorticoid (GC) therapy. Using a Cre-
transgenic mouse line, we now demonstrate that
GCs are unable to repress bone formation in the
absence of glucocorticoid receptor (GR) expression
in osteoblasts as they become refractory to hor-
mone-induced apoptosis, inhibition of proliferation,
and differentiation. In contrast, GC treatment still
reduces bone formation in mice carrying a muta-
tion that only disrupts GR dimerization, resulting in
bone loss in vivo, enhanced apoptosis, and sup-
pressed differentiation in vitro. The inhibitory GC
effects on osteoblasts can be explained by a mecha-
nism involving suppression of cytokines, such as
interleukin 11, via interaction of the monomeric GR
with AP-1, but not NF-kB. Thus, GCs inhibit cyto-
kines independent of GR dimerization and thereby
attenuate osteoblast differentiation, which accounts,
in part, for bone loss during GC therapy.
INTRODUCTION
Although glucocorticoids (GCs) are widely used to treat allergic
and autoimmune diseases, their application is accompanied byCsevere side effects, including detrimental effects on the skeleton
(James et al., 2007). Reduction of bone mass by GCs is believed
to involve systemic effects and/or direct effects on bone cells
(Canalis et al., 2007), leading to induction of apoptosis in osteo-
blasts and osteocytes (Weinstein et al., 1998) and/or suppres-
sion of their differentiation. Whereas low doses of GCs stimulate
(Shalhoub et al., 1992), high doses inhibit osteoblast differentia-
tion, the latter being related to the inhibition of postconfluential
proliferation (Smith et al., 2000). Suppression of osteoblast
function could be a consequence of decreased expression of
genes involved in bone formation, such as collagen type 1
(Col1a1) and Runx2, or could be due to antagonizing the BMP-
andWnt-signaling pathways (Canalis et al., 2007). Besides oste-
oblasts, modulation of osteoclast activity also appears to
contribute to GC-induced osteoporosis (GIO). GCs induce the
synthesis of receptor activator for nuclear factor (NF)-kB ligand
(RANKL), an essential stimulator of osteoclastogenesis (Hofba-
uer et al., 1999). In addition, they prolong the longevity of osteo-
clasts in vivo but decrease their bone-degrading activity and
seem to influence bone formation via the GR in osteoclasts (Jia
et al., 2006; Kim et al., 2006).
The majority of GC effects are mediated via the glucocorticoid
receptor (GR), a widely expressed member of the nuclear
receptor superfamily. Following hormone binding, the GR alters
gene expression via several modes of action, including its
binding as dimers to GC-responsive elements (GRE) present in
the promoter of hormone-responsive genes and interaction of
the monomeric receptor with DNA-bound transcription factors
such as NF-kB, AP-1, IRF-3, or STAT5 (Kassel and Herrlich,ell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc. 517
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believed to underlie, in part, the anti-inflammatory effects of
GCs, and dimerization of the GR is hypothesized to contribute
to many of the side effects. This view is supported by the finding
that interaction with proinflammatory transcription factors is
preserved in GRdim mice carrying a dimerization-deficient GR,
whereas induction of GRE-dependent transcription is abolished
(Reichardt et al., 1998, 2001). However, there is a requirement for
GR dimerization to achieve full suppression of inflammation in
contact allergy, as GC treatment is therapeutically inefficient in
GRdim mice (Tuckermann et al., 2007).
The aim of this study was to attain a better understanding of
the mode of GR action underlying GIO and the primary type of
bone cells targeted byGCs.We demonstrate that theGR in oste-
oblasts is required to preserve full bone integrity under physio-
logical conditions, that bone loss induced by therapeutic GC
treatment is mediated by the GR in osteoblasts and independent
of its dimerization, and that the monomeric GR is sufficient to
impair osteoblast differentiation by suppressing osteoblast-
derived cytokines such as interleukin 11 (IL-11).
RESULTS
Endogenous Glucocorticoid Action in Osteoblasts
Increases Bone Mass, but Not Skeletal Development
We initially asked whether endogenous GCs influence the devel-
opment of the skeleton by using GR knockout (GRnull) mice. Aliz-
arin red/Alcian blue staining did not reveal any differences in
cartilage and calcified tissues in GRnull compared to wild-type
E18.5 fetuses, and X-ray analysis showed similar bone mineral
densities (Figures S1A and S1B available online). The lack of
gross alterations in growth plate dimensions and a similar extent
of calcified bone revealed by von Kossa staining indicated that
the development of skeletal tissues in GRnull fetuses is normal
(Figures S1C and S1D).
To allow investigations of GC actions in adult bone, we disrup-
ted theGR gene specifically in the osteoblast lineage by crossing
GRfloxmice (Troncheet al., 1999)with anosteoblast-specificCre-
transgenic mouse line (Runx2Cre), thereby obtaining GRRunx2Cre
mice. Of note, efficient recombination at all sites of endochondral
and intramembranous bone formation, particularly in periosteal
cells, osteoblasts, and osteocytes, but not in osteoclasts, was
observed when Runx2cre mice were crossed to a Rosa26
reporter strain (Figure S2). In accordance with all known sites of
Runx2 expression, GRRunx2Cre displayed almost complete
recombination of theGR-floxallele in longbones, to a largeextent
in calvaria, and to a minor part in cartilage. Recombination was
undetectable in other mesenchymal tissues, i.e., muscle or fat
(Figures S2G, S2I, and S2J). Thus, the GR is efficiently deleted
in the osteoblastic lineage in GRRunx2Cre mice. Compared to
control animals, females lacking the GR in osteoblasts exhibited
no growth defects. Male mice showed a small increase in rump,
but not in tibia length, indicating a potentially minor role of the
GR in the growth of the spine in males (Table S1).
Microcomputer tomography (Micro-CT) analysis and bone
histomorphometry of calcified vertebral sections of 3-month-
old female and male GRRunx2Cre mice revealed a modest but
highly significant decrease of bone density compared to GRflox
mice (Figures 1A, 1B, and data not shown). Whereas trabecular518 Cell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc.thickness was not altered, the decrease was, rather, due to
diminished trabecular numbers and, consequently, an increase
in trabecular spacing (Figure 1B). Numbers of osteoblasts, oste-
oblast surface, osteocytes, and osteoclast parameters were not
significantly changed (Figure 1C). We therefore hypothesized
that lack of the GR affects the differentiation toward functional
osteoblasts, rather than their numbers per se. Indeed, as sug-
gested by previous reports on mouse models deficient in GC
action (Durbridge et al., 1990; Kalak et al., 2009; Sher et al.,
2004, 2006), calvarial osteoblasts from GR-deficient mice dis-
played a diminished differentiation potential in terms of alkaline
phosphatase (ALP) expression and bone nodule formation
(Figure 1D). Accordingly, expression of marker genes for osteo-
blast differentiation and function, such as Runx2, Col1a1, and
Bglap2 (osteocalcin), was reduced (Figure 1E).
GR in Osteoblasts Mediates GC Suppression
of Bone Formation
To address the role of the GR in osteoblasts in GC-induced bone
loss, GRRunx2Cre and GRflox mice were treated with the clinically
relevant GR agonist prednisolone for 2 weeks. As expected,
prednisolone led to a reduced bone mineral density in vertebral
bones of wild-type mice due to decreased trabecular thickness.
In contrast, these parameters were not affected in GRRunx2Cre
mice (Figures 2A and 2B). Resorption, as assessed by deoxypyr-
idinoline (DPD/Cr) levels, was not increased by prednisolone but,
rather, was slightly decreased in mice of both genotypes (Fig-
ure 2C); however, osteoclast numbers were not affected (Fig-
ure 2D). In contrast, the numbers of osteocytes, osteoblasts
(Figure 2D), and the osteoblast surface (data not shown) were
decreased in GRflox mice after prednisolone treatment, whereas
the same parameters were unaltered in GRRunx2Cre mice.
Most importantly, whereas prednisolone caused an almost
complete inhibition of bone formation as determined by dynamic
histomorphometry following dual calcein labeling in vertebrae of
wild-type mice, GRRunx2cre mice were fully protected (Figures 2E
and 2F). Because resorption was only slightly altered after pred-
nisolone treatment, this complete block of bone formation is
presumably the major cause for prednisolone-induced bone
loss in wild-type mice. Of note, prednisolone did not alter TUNEL
and BrdU pulse labeling directly within bone tissue (Figure S3).
But osteoblastogenesis, in terms of colony-forming units of oste-
oblasts (CFU OBs), was strongly impaired in GRflox mice, but not
in GRRunx2Cre mice, after 3 days of prednisolone treatment
(Figure 2G).Most strikingly, the expression of themarker for func-
tional osteoblasts, Col1a1, was strongly reduced after 3 days of
prednisolone in GRflox mice, whereas it remained unchanged in
GRRunx2Cremice (Figure 2H), indicating suppression of osteoblast
differentiation and function via the GR in these cells.
TheGR inMyeloid Cells Does Not Affect Bone Formation
To test whether the GR in osteoclasts influences bone formation
during GC treatment, GRLysMCre mice lacking the GR in myeloid
cells, such as monocytes, macrophages, neutrophils, and oste-
oclasts (Tuckermann et al., 2007; J.P.T., unpublished data), were
treated with prednisolone for 2 weeks. The bone formation rate
was similarly reduced in GRLysMCre and wild-type mice (Figures
2I and 2J), thus excluding a role for these cells in mediating
GC-induced bone loss.
Figure 1. Reduced Bone Mass in GRRunx2Cre Mice
(A) Micro-CT reconstruction of the trabecular part of vertebral L6 bodies of 10-week-old female GRRunx2cre and GRflox mice.
(B and C) Histomorphometry of (B) bone volume/tissue volume (BV/TV), trabecular thickness (TbTh), trabecular numbers (TbN), and trabecular spacing (TbSp)
and (C) osteoblast number/bone perimeter (Ob.N/B.Pm), osteoblast surface/bone surface (Ob.S/BS), osteoclast number/bone perimeter (Oc.N/B.Pm), and oste-
oclast surface/bone surface (Oc.S/BS).
(D) Primary osteoblasts derived fromwild-type (wt) andGRnull micewere inducedwith osteogenic differentiationmedium, and differentiationwas analyzed by ALP
staining after 10 days and alizarin red after 20 days.
(E) Osteoblast mRNA expression levels (arbitrary units normalized to actin) for Runx2, Col1a1 (10 days of differentiation), and Bglap2 (20 days) determined by
qRT-PCR.
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 8 in (B) and (C). n = 3 in (E).
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of GR Dimerization
Although it had been hypothesized that GR dimerization was
essential for many side effects of GC therapy, its role in bone
loss has not been previously investigated. Therefore, GRdim
mice carrying a dimerization-defective GR were treated withCprednisolone. In contrast to GRRunx2Cre mice, bone formation
was similarly repressed in GRdim and wild-type mice, and bone
mass and trabecular thickness of the vertebrae were reduced
to a comparable degree (Figures 3A–3D). This was again accom-
panied by a strong reduction of osteoblast and osteocyte
numbers (Figure 3E), as well as osteoblast surface (data notell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc. 519
Figure 2. Prednisolone Reduces Bone Formation Dependent on the GR in Osteoblasts
(A and B) Vertebral bodies of 10-week-old female GRRunx2cre and GRflox mice treated with placebo (Plac) or prednisolone (Pred; 12.5 mg/kg/day) for 2 weeks were
analyzed by (A) von Kossa staining of undecalcified sections and (B) histomorphometry of BV/TV and TbTh.
(C) DPD/Cr levels in urine of mice after prednisolone treatment at indicated times.
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Glucocorticoid Receptor in Osteoporosisshown) in both genotypes. Osteoblastogenesis in vitro was
as efficiently suppressed in GRdim as in wild-type mice, and
Col1a1 expression was similarly reduced in both genotypes
(Figures 3F and 3G). Whereas osteoclast numbers were not
changed, resorption was slightly decreased in both mouse
strains (Figures 3E and 3H).Dimerized GR Affects Osteoblast Proliferation,
but Not Apoptosis and Differentiation
Primary osteoblasts fromwild-type, GRnull, and GRdimmice were
cultured in vitro to determine the contribution of GR dimerization
toGC effects on osteoblasts. Proliferation of preconfluent preos-
teoblasts isolated from neonatal calvaria was lower in cultures of
both GRnull and GRdim cells as compared to wild-type controls,
suggesting that the GR promotes osteoblast expansion in
the presence of basal GC concentrations (Figure 4A). In contrast,
treatment with dexamethasone (Dex) completely prevented
expansion of wild-type cells but did not affect GRnull and GRdim
cultures. Thus, GR dimerization is required for permissive and
repressive GC activities on osteoblast expansion.
Postconfluential proliferation after exposure to osteogenic
conditions has been reported to accompany osteoblastic differ-
entiation in vitro (Smith et al., 2000). Ki-67-stained wild-type cells
confirmed reduction of proliferation by Dex after 24 hr until 96 hr
(Figure S4B). In contrast, postconfluential proliferation of GRdim
and GRnull cells was entirely unaffected by Dex (Figure 4B).
In addition, Dex-induced apoptosis was observed in wild-type
and GRdim cells, but not in GRnull cells (Figures 4C and S4A).
This is consistent with the slight reduction in postconfluential
cell numbers by Dex in wild-type and GRdim, but not in GRnull
cells (Figures 4D andS4C). ALP activity andmatrixmineralization
were inhibited by Dex treatment of wild-type and GRdim, but
not of GRnull osteoblasts (Figures 4E and 4F). Efficient downregu-
lation of the osteoblastic markers Runx2, Akp1, Col1a1, and
Bglap2 confirmed inhibition of osteoblast differentiation of wild-
type andGRdim cells. In contrast, no repressive effect of Dex was
observed for GRnull osteoblasts (Figures 4G–4J).The Monomeric GR in Osteoblasts and Osteoclasts
Affects Osteoclastogenesis
Because osteoblasts can stimulate the formation of osteoclasts,
cocultures of osteoblasts with wild-type, GRnull, and GRdim fetal
liver cells serving as osteoclast progenitors were established.
Irrespective of whether the GR was present in osteoclasts,
cocultures with GRnull osteoblasts under basal conditions led
to the generation of fewer tartrate-resistant alkaline phospha-
tase-positive multinuclear cells (TRAP MNCs) as compared to
wild-type osteoblasts (Figure 5A). This indicates that the GR in
osteoblasts contributes to osteoclastogenesis under low-dose
GC conditions. A pharmacological dose of Dex reduced the(D) Histomorphometry of osteoblast number/bone perimeter (NOb/BPm), osteo
(NOc/BPm).
(E and F) Fluorescent micrographs of (E) dual calcein labeling and (F) its quantita
(G and H) Number of (G) CFU OBs within the bone marrow/leg (femur and tibia) a
treated with placebo or prednisolone for 3 days.
(I and J) Fluorescent micrographs of (I) dual calcein labeling and (J) its quan
control mice.
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 5–6.
Cnumber of TRAPMNCs in cocultures independent of GR expres-
sion in the osteoclasts (Figure 5A), again highlighting a major
contribution of the GR in osteoblasts. Of interest, Dex also
repressed osteoclastogenesis when we cocultivated GRnull
osteoblasts with wild-type fetal liver cells, but not when the GR
was absent from both cell compartments (Figure 5A). Thus, the
GR in both osteoblasts and osteoclasts mediates reduction of
TRAP-positive cells by GCs.
Dimerization of the GR in osteoblasts was neither required for
basal osteoclastogenesis nor for suppression of osteoclasto-
genesis by Dex (Figure 5B). It is noteworthy that GRdim osteo-
clast differentiation from progenitor cells in the presence of
M-CSF and RANKL was as efficiently prevented by Dex as in
wild-type controls in terms of TRAP MNCs capable of resorbing
bone surfaces (Figures 5D–5F). Therefore, repression of osteo-
clastogenesis by GCs occurs independently of GR dimerization
in both osteoblasts and osteoclasts. Suppression of osteoblast
differentiation, however, is cell autonomous and is not influenced
by the GR in osteoclasts. In cocultures, ALP-positive osteoblasts
were reduced only when the GR was present in osteoblasts but
were independent of its presence in osteoclasts (Figure 5C).GCs Inhibit Osteoblastogenesis in the Absence
of NF-kB Activity
The dimerization-defective receptor in GRdim mice is strongly
impaired in direct DNA binding but is still able to suppress oste-
oblast differentiation. Thus, a GR dimer-independent tethering
mechanism with other transcription factors, such as NF-kB,
could be crucial in this process. To test this hypothesis, we
employed primary osteoblasts expressing a nondegradable
N-terminal truncated IkBa (dNRunx2Cre). By preventing its phos-
phorylation by IkB kinases, this molecule acts as a dominant
suppressor of p65/p50 activation (Schmidt-Ullrich et al., 2001),
whereas GR activity is not affected. Indeed, NF-kB activity was
strongly reduced, as indicated by the impaired nuclear translo-
cation of NF-kB p65 after tumor necrosis factor (TNF)a treatment
(Figure 6A). Independent of diminished NF-kB activity, osteo-
blast apoptosis was normal after Dex treatment (Figure 6B), and
their differentiation was still efficiently inhibited by Dex based on
reduced ALP activity and lower Col1a1 and Runx2 expression
(Figures 6C–6F). Thus, it is unlikely that GCs inhibit bone forma-
tion via interference of the GR monomer with NF-kB activity.Tethering of GR to AP-1 Sites Inhibits Il11 Expression,
Leading to Suppression of Osteoblast Differentiation
To determine the molecular mechanism used by the monomeric
GR to suppress osteoblast differentiation, we performed quanti-
tative PCR to identify genes potentially involved in this process.
First, we confirmed lack of induction of known GRE-dependent
genes by Dex in GRdim osteoblasts, namely the GC-inducedcyte number/bone area (NOy/BAR), and osteoclast number/bone perimeter
tive analysis of bone formation rate/bone surface (BFR/BS).
nd (H) qRT-PCR-determined Col1a1 mRNA expression in long bones of mice
titative analysis of BFR/BS in tibiae of GRLysMcre and corresponding GRflox
ell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc. 521
Figure 3. GRdim Mice Respond to Prednisolone with Suppression of Bone Formation
(A and B) Fluorescent micrographs of (A) dual calcein labeling and (B) its quantitative analysis of BFR/BS in vertebrae of GRdim and wild-type (wt) mice treated as
described in Figure 2.
(C) Vertebral bodies were analyzed by von Kossa staining of undecalcified sections.
(D and E) Histomorphometry of (D) BV/TV, TbTh, (E) NOb/BPm, NOy/BAR, and NOc/BPm.
(F and G) Number of (F) CFUOBs within the bone marrow/leg and (G) qRT-PCR-determinedCol1a1mRNA expression in long bones of mice treated with placebo
or prednisolone for 3 days.
(H) DPD/Cr levels in urine of mice after prednisolone treatment at indicated times.
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 5–6.
Cell Metabolism
Glucocorticoid Receptor in Osteoporosisleucine zipper (Tsc22d3, GILZ), the circadian rhythm gene Per1,
and the recently identified GR target gene Klf15 (Yoshikawa
et al., 2009) in GRdim osteoblasts (Figures 7A–7C). In contrast,
several growth factors and cytokines were similarly downregu-
lated in both wild-type and GRdim osteoblasts. Among them
were the nerve growth factor 2 (Ngf2), the heparin binding-
epidermal growth factor (Hbegf), interleukin-6 (Il6), the leukemia522 Cell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc.inhibitory factor (Lif), and interleukin-11 (Il11), which were down-
regulated by GCs in both wild-type and GRdim osteoblasts
(Figures S5A–S5C, 7D, and 7E).
Because defective IL-11 signaling causes reduced bone
formation in mice (Sims et al., 2005), we analyzed GC regulation
of Il11 in embryonic bone organ cultures (detection of IL-11 in
adult bones was difficult due to the small fraction of osteoblasts
Figure 4. Dimerization of the GR Is Required for Inhibition of Osteoblast Proliferation, but Not for Induction of Apoptosis and Suppression of
Differentiation
(A) Primary mouse osteoblasts were treated without (Co) or with 1 mM Dex (Dex), and cell numbers were assessed at indicated days.
(B–D) Primary osteoblasts were grown until confluence and were induced with osteogenic differentiation medium (OI) or in addition treated with 1 mM Dex
(OI+Dex). At day 3, (B) Ki-67 content and (C) TUNEL labeling were analyzed, whereas (D) cell numbers were counted at day 10 using automated microscopy.
(E and F) Primary osteoblasts after osteogenic induction, with or without Dex, were stained for ALP activity and calcification with alizarin red at indicated days.
(G–J) qRT-PCR-determined osteoblast mRNA expression levels of Akp1(ALP), Runx2, Col1a1 (10 days of differentiation), and Bglap2 (20 days).
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 3.
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Glucocorticoid Receptor in Osteoporosisin the entire bone). Dex suppressed Il11 expression in wild-type
and GRdim bones, but not in those from GRRunx2Cre mice
(Figure 7F). Thus, Il11 expression in the entire bone is similarly
regulated by GCs as in isolated osteoblasts.
Suppression of Il11 in cells and long bones from GRdim mice
points toward regulation by a tethering mechanism of the GR,
e.g., binding to NF-kB or AP-1. Because Dex efficiently reduced
Il11 mRNA levels in osteoblasts that display strongly impairedCNF-kB activity (Figure 7G), NF-kB is neither involved in Il11
expression nor a target for suppression by the GR. In contrast,
Il11 expression under osteogenic conditions was strongly
impaired in mouse embryonic fibroblasts (MEFs) lacking c-Jun/
AP-1 in comparison to wild-type MEFs (Figure 7H). Furthermore,
Dex diminished Il11 mRNA levels in wild-type, but not in c-Jun
knockout MEFs (Figure 7H), suggesting that c-Jun as a major
component of the AP-1 complex drives Il11 transcriptionell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc. 523
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performed chromatin immunoprecipitation of wild-type and
GRdim MEFs, in which Il11 is repressed in a GR dimerization-
independent manner (Figure S5D). A DNA element of the Il11
promoter containing two adjacent functional AP-1-binding sites
(Tohjima et al., 2003) was amplified from wild-type and GRdim
MEFs, confirming that the monomeric GR indeed interacts with
the AP-1 site on the Il11 promoter (Figure 7I). Thus, tethering of
the GR monomer to AP-1 forms the basis of GC-mediated inhi-
bition of Il11.
To investigate whether inhibition of cytokine and growth fac-
tor expression underlies the Dex-induced reduction of osteo-
blast number and differentiation, we ectopically added the
previously identified factors to osteoblasts during osteogenic
induction in the presence or absence of Dex. NGF2 and IL-6
rescued neither the reduced cell numbers nor the impaired
differentiation (Figures S6A, S6B, S7A, and S7B). HB-EGF sig-
naling evoked by epidermal growth factor in osteoblasts (Chien
et al., 2000) counteracted the reduction in cell number caused
by Dex (Figure S6C) but did not prevent the inhibition of differen-
tiation (Figure S7C). In contrast, both LIF and IL-11, despite not
rescuing the inhibitory effect of Dex on osteoblast cell counts
(Figures S6D and S6E), potently antagonized the GC-mediated
suppression of differentiation (Figures S7D, 7J, and 7K). In
particular, Dex suppression of ALP activity, ofRunx2 expression,
and of calcification was fully restored in the presence of IL-11
(Figures 7K and 7L). We conclude that LIF and, particularly,
IL-11 are crucial factors in GIO.DISCUSSION
GIO is a major side effect of GC therapy, but despite being
aware of this problem for decades, the role of the GR in bone
development, differentiation, and homeostasis has not been fully
resolved. Using conditional and function-selective GR knockout
mice, we establish an anabolic role of the GR in osteoblasts
under physiological conditions and a catabolic function of the
GR monomer at pharmacological exposure to GCs.Anabolic Role of the GR in Bone Integrity
GRnull embryos did not reveal any major function of the GR in
bone growth and architecture during development. Adult mice
lacking the GR in osteoblasts also showed overall normal bone
growth and geometry, with the exception of a slight increase in
rump length in males. We cannot rule out that this is due to the
minor recombination observed in the cartilaginous growth
plates, which will be clarified with cartilage-specific GR mutantFigure 5. Osteoclastogenesis Is Suppressed by GCs by the GR in Oste
Osteoblastogenesis Depends Solely on the Osteoblast GR
(A and B) (A)Wild-type and GRnull osteoblasts and (B) wild-type andGRdim osteobl
in the presence of vitamin D3, with or without Dex. After 7 days of culture, wells
(C) Wild-type and GRnull osteoblasts (OB) were cultured with fetal liver cells deri
10 days of coculture under osteogenic conditions with or without Dex.
(D) Wild-type- and GRdim-derived bone marrow-derived macrophages (BMDMs)
presence of Dex. TRAP MNCs were determined after 5 days.
(E and F) Wild-type and GRdim BMDMs were cultured with M-CSF and RANKL in
phosphate to determine resorption area after 5 days of culture.
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 4. Scale bar, 400 mm.
Cmice. In contrast, bone mass and trabecular number were lower
in both female and male GRRunx2Cre mice. This is in line with the
decreased bone mass observed in adrenalectomized rats
(Durbridge et al., 1990) and in Hsd11b2-overexpressing mice in
which GC activity is specifically disrupted in osteoblasts (Sher
et al., 2004, 2006). In agreement with previously described
stimulatory effects of GCs on osteoblastic cells (Ishida and
Heersche, 1998; Shalhoub et al., 1992), we found reduced prolif-
eration and a diminished differentiation capacity of cultured
GRnull osteoblasts. GRdim mice exhibited normal bone mass
and trabecular numbers under physiological conditions. Given
that GRdim osteoblasts showed normal differentiation despite
impaired proliferation, we conclude that effects on the former
are more crucial for anabolic GC effects on bone.GCs Inhibit Bone Formation via the GR in Osteoblasts
Our data support a model in which the GR in osteoblasts is
essential for GIO because prednisolone failed to reduce the
bone formation rate, bone mass, and trabecular thickness in
GRRunx2Cre mice. In addition, GC-mediated suppression of
Col1a1 required the presence of the GR in osteoblasts. The
requirement of the GR also clearly shows that the prednisolone
dose used here, which was established to be effective in mice
with the FVB/N background strain, displays no unspecific toxic
effects. Osteoclast numbers were hardly affected by predniso-
lone, whereas osteoblast and osteocyte counts were diminished
in wild-type, but not in GRRunx2Cre, mice. In contrast to other
studies that detected a marginal increase (Weinstein et al.,
1998), we did not detect additional apoptosis of osteoblasts
and osteocytes by prednisolone treatment in vivo. This discrep-
ancy may be due to different mouse strains. Thus, apoptosis of
mature osteoblasts would not explain the strong decrease in
osteoblast numbers. This effect, rather, becomes effective at
the osteoblast progenitor level because CFU OBs were already
reduced in wild-type animals after 3 days of treatment. The
observed reduction of osteocytes by 20%–35%, in combina-
tion with no observable changes in empty lacunae (data not
shown), also argues against an enhanced apoptosis and can
only be explained by an absence of bone formation, allowing
the removal of osteocyte-containing bone by still ongoing bone
resorption.
In contrast to GRRunx2Cre mice, we found a similar reduction of
bone mass, trabecular thickness, bone formation, osteoblast
numbers, and CFU OBs by GCs in wild-type and GRdim mice.
These results clearly show that the GR in osteoblasts, but not
its dimerization function, is required for inhibition of bone forma-
tion and, consequently, bone loss.oblasts and Osteoclasts, Independent of GR Dimerization, whereas
asts were cultured with fetal liver cells (FL) derived fromwild-type or GRnull mice
were stained with TRAP, and TRAP MNCs were counted.
ved from wild-type or GRnull mice as in (A). ALP staining was performed after
were cultured with M-CSF (50 ng/ml) and RANKL (30 ng/ml) in the absence or
the presence or absence of Dex in osteological chambers coated with calcium
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Figure 6. Lack of NF-kB Activity Does Not Change the Response of Osteoblasts Toward GCs
(A) Wild-type and dNRunx2Cre osteoblasts were treated with TNFa for 30 min. Nuclear and cytoplasmic extracts were analyzed by immunoblotting for p65, actin,
and polymerase II.
(B–D) Primary osteoblasts were grown until confluence and treated as described in Figure 4A. (B) TUNEL labeling was performed after 3 days. After 10 days, ALP
staining (C) and quantitative ALP activity (D) were examined.
(E and F) qRT-PCR-determined osteoblast mRNA expression levels of Col1a1 and Runx2 (10 days of differentiation).
Data represent mean ± SEM. *p < 0.05. n = 3.
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Cell-autonomous effects of the GR in osteoclasts can lead to
GC-enhanced bone resorption (Jia et al., 2006; Weinstein
et al., 2002; Yao et al., 2008). We found a slightly decreased
resorptive activity during the entire 14 days of GC treatment.
Nevertheless, in the absence of de novo bone formation, the526 Cell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc.residual resorptive activity after prednisolone administration
was apparently sufficient to lead to GC-induced bone loss in
wild-type and GRdim mice. This explains why interfering with
bone resorption using bisphosphonates (Weinstein et al., 2002)
or inhibitory anti-RANKL antibodies (Hofbauer et al., 2009)
ameliorates bone loss in GIO models.
Figure 7. Differential Gene Regulation in GRdim Osteoblasts and Bone Organs by GCs and Involvement of AP-1 in Suppression of IL-11 in
Osteoblast Differentiation
(A–E) Primary osteoblasts were grown until confluence and treated as described in Figure 4A. qRT-PCR-determined mRNA expression levels of Tsc22d3, Per1,
Klf15, Lif, and Il11 after 6 hr.
(F–H) qRT-PCR-determinedmRNA expression level of Il11 in organ cultures of GRmutant fetal hind legs (F), in dNRunx2Cre osteoblasts (G), and in c-junnull MEFs (H)
after 6 hr treatment.
(I) Chromatin immunoprecipitation of MEFs after 6 hr. Anti-GR precipitation revealed PCR-amplified fragments of the Il11 promoter encompassing functional AP-
1 sites. IgG precipitation served as negative control and amplification of the input as positive control.
(J) Primary wild-type osteoblasts were differentiated with or without Dex and in the presence or absence of recombinant IL-11 10 ng/ml. At day 10, ALP activity
was determined, and at day 20, alizarin red staining was performed.
(K) Quantification of ALP-positive cells treated as in (J) after 10 days.
(L) qRT-PCR-determined Runx2 mRNA expression level in cells treated as in (J) after 10 days.
Data represent mean ± SEM. *p < 0.05, **p < 0.01. n = 3.
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Glucocorticoid Receptor in OsteoporosisIn contrast to unaffected osteoclast numbers in vivo, pharma-
cological doses of GCs repressed osteoclastogenesis via theGR
in osteoblasts and osteoclasts in vitro. The latter observation is inCline with a report by Kim et al. (2006) showing that Dex inhibits
osteoclast formation and spreading in vitro by a mechanism
dependent on the GR in osteoclasts. The absence of changesell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc. 527
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Glucocorticoid Receptor in Osteoporosisof osteoclast numbers in vivo might be explained by a slow turn-
over of bone-residing osteoclasts, thus concealing the inhibitory
effect observed in the coculture experiments. Neither the direct
inhibitory effects of GCs on isolated osteoclasts nor the indirect
effects on osteoclastogenesis mediated by osteoblasts require
GR dimerization.
Osteoclastogenesis proceeded normally in GR-deficient oste-
oclast progenitor cells. Likewise, we did not observe any differ-
ences in bone mass and trabecular thickness under physiolog-
ical conditions in GRLysMCre mice lacking the GR in osteoclasts
(data not shown). However, bone formation in GRLysMCre mice
was similarly reduced upon GC treatment as in wild-type ani-
mals. This is in striking contrast to a previous report using the
same animal model (Kim et al., 2006) but is in line with a study
using TRAP-Hsd11b2 transgenic mice in the sense that GCs
reduce osteoblast numbers and bone formation even when GC
actions in osteoclasts cannot occur (Jia et al., 2006). However,
an important role of the GR in osteoclasts for the increased
bone resorption observed in humans and some mouse strains,
such as Swiss Webster mice, cannot be excluded.
Inhibition of Bone Formation and Osteoblastogenesis
Is Independent of GR Dimerization
We have described complete suppression of osteoblast dif-
ferentiation in vitro and GC-induced bone loss in vivo in the
absence of GR-DNA binding. Osteoblast differentiation in GRdim
calvarial osteoblasts was as efficiently inhibited by GCs as in
wild-type cells; however, only a low level of apoptosis was
induced by GCs in wild-type and GRdim osteoblasts in vitro.
More strikingly, we failed to detect enhanced apoptosis in vivo
at several time points, nor did we detect a change of empty
lacunae, an indication of apoptotic loss of osteocytes (data not
shown). These findings argue against an important role of cell
death in GIO, as previously proposed (Weinstein et al., 1998).
Proliferation of GRdim osteoblasts could not be inhibited by
GCs either before or after confluence. In view of the previously
reported role of proliferation for subsequent osteoblastic
differentiation of MC-3T3 cells (Smith et al., 2000), the uncou-
pling of proliferation and differentiation in GRdim osteoblasts is
surprising. Because osteoblast numbers, osteoblastogenesis,
Col1a1 expression, and bone formation were reduced by GCs
in GRdim mice, we propose that inhibition of osteoblastogenesis,
rather than inhibition of cell proliferation accounts for these
effects.
Repression of AP-1-Dependent IL-11 Inhibits
Osteoblastogenesis
Activation of bona fideGRE-dependent genes, such as Tsc22d3,
Per1, and Klf15 (Balsalobre et al., 2000; Rogatsky et al., 2003;
Yoshikawa et al., 2009), was strongly impaired in GRdim osteo-
blasts, whereas repression of several genes encoding growth
factors and cytokines was not affected. Because inhibition of
osteoblastogenesis by GCswas similar in wild-type and in GRdim
mice, we hypothesized that this was most likely achieved
through repression of soluble factors via the monomeric GR. In
line with this, we found that Hbegf, Lif, and Il11 were inhibited
by GCs independently of GR dimerization. In agreement to the
observation that HB-EGF inhibits differentiation of mesenchymal
stem cells (Krampera et al., 2005), it also exerted an inhibitory528 Cell Metabolism 11, 517–531, June 9, 2010 ª2010 Elsevier Inc.effect on osteoblast differentiation. Thus, HB-EGF is unlikely to
play a role in GIO. In contrast, LIF and IL-11 counteracted
suppression of osteoblast differentiation by Dex in culture.
Although Lif is a target gene of AP-1 (Bozec et al., 2008) and
induces aberrant bone growth in mice (Metcalf and Gearing,
1989), we focused on Il11 because, in contrast to Lif, it was
induced under osteogenic conditions in osteoblasts (data not
shown). In entire embryonic bones, suppression of Il11 by GCs
requires the GR in osteoblasts, but not its dimerization. This
points toward an interaction of the GR monomer with other tran-
scription factors. Our analyses indicate that interaction with
NF-kB is not essential for GIO because primary osteoblasts
from dNRunx2Cre mice that are impaired in p65 nuclear transloca-
tion and thus NF-kB activity responded normally to GCs in terms
of diminished cell numbers, induction of apoptosis, inhibition of
differentiation, and suppression of Il11. Indeed, inhibition of
NF-kB leads to enhanced osteoblast differentiation and bone
mass instead of diminished osteoblast function (Chang et al.,
2009). However, interaction of the monomeric GR with AP-1
appears to be crucial for inhibition of osteoblast differentiation
by GCs. Unlike in wild-type cells, Il11was hardly induced in cells
lacking c-Jun, and the residual expression was unaltered by Dex.
Consistently, we demonstrated recruitment of the wild-type and
the GRdim receptor to two adjacent AP-1 sites in the Il11
promoter (Tohjima et al., 2003). Finally, IL-11 was able to rescue
Dex-mediated inhibition of osteoblast differentiation. In line with
our results, IL-11 enhances bone formation when overexpressed
in mice (Takeuchi et al., 2002), and targeted deletion of the IL-11
receptor alpha leads to decreased bone formation (Sims et al.,
2005). Given that the AP-1 target genes Il11 and Lif are able to
rescue Dex-mediated inhibition of osteoblast differentiation,
a tethering mechanism involving the monomeric GR and AP-1
presumably underlies repression of cytokines and growth
factors during GIO.
Conclusions
We show in this study that the capacity of the monomeric GR to
inhibit AP-1-controlled cytokines, such as IL-11 or LIF, is central
to the suppression of osteoblast differentiation and that inhibi-
tion of bone formation by GCs is independent of GR dimeriza-
tion. Consequently, tethering of the GR to AP-1 not only contrib-
utes to the anti-inflammatory effects of GCs, but is also essential
for provoking GIO. In contrast, repression of NF-kB-dependent
genes does not seem to be involved in osteoblast differentiation,
whereas it plays a major role in the anti-inflammatory activities
of GCs.
Therefore, our study proposes that selective GR agonists,
which would fail to suppress AP-1-dependent gene expression
but are still capable of inhibiting NF-kB-dependent gene regula-
tion, could be beneficial in anti-inflammatory activities while not
concomitantly inducing GIO.
EXPERIMENTAL PROCEDURES
Generation of Runx2Cre Mice
A 150 kb BAC covering the Runx2 locus (Genome System BAC Library, RZPD,
Germany) was modified by inserting a codon-improved Cre recombinase at
the translational start site of the bone-specific distal promoter (P1) of the
Runx2 gene (Stock and Otto, 2005) by ET recombination, as previously
described (Casanova et al., 2001). The modified BAC was microinjected into
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Glucocorticoid Receptor in Osteoporosisthe pronucleus of oocytes from FVB/N mice, and three different founder
lines were established. One line was chosen for crossing with GRflox mice
based on its expression pattern.
Animal Experimentation
All animal experiments were performed in accordance with accepted stan-
dards of animal welfare and with permission of the responsible authorities of
Baden-Wu¨rttemberg and Thu¨ringen. GRdim (Reichardt et al., 1998) and GRflox
(Tronche et al., 1998) were backcrossed to the FVB/N background for at least
four generations. dNflox (Schmidt-Ullrich et al., 2001) and GRnull (Tronche et al.,
1998) were on a miced background and 129/SvJ background, respectively.
Cre activity was monitored using Rosa26 reporter mice by whole-mount
b-galactosidase staining (Soriano, 1999). GRLysMCre mice (Tuckermann et al.,
2007) were backcrossed to Balb/c for five generations. To induce osteopo-
rosis, prednisolone (or a placebo control) was applied for 14 days by subcuta-
neous implantation of slow-release pellets, resulting in a calculated dose of
12.5 mg/kg/d (15 mg; 60 day release; Innovative Research of America, Inc.)
in 10-week-old female mice.
Cell Culture and qRT-PCR Analysis
Primary osteoblasts were isolated from either embryonic (E18.5) or neonatal
calvaria by sequential digestions and cultivated as previously described (David
et al., 2005). c-Jun-deficient cells were obtained from previously described
mice (Schreiber et al., 1999). Cells were passaged once before induction of
osteogenic differentiation by 100 mg/ml ascorbic acid and 5 mM b-glycero-
phosphate in the presence or absence of 1 mM Dex (Sigma). Differentiation
of osteoblasts was determined by staining for ALP activity (ALP kit, Sigma or
ELF Phosphatase Detection Kit, ATCC) or by alizarin red staining (Sigma) at
indicated time points. Apoptosis was detected by In Situ Cell Death Detection
Kit (Roche) and proliferation with fluorescent immunohistochemistry using
mouse anti-Ki-67 (BD PharMingen) and Alexa Fluor 594-labeled donkey anti-
mouse IgG (Molecular Probes). Quantification of the stainings and cell
numbers according to DAPI labeling was performed by automatedmicroscopy
using Cellomics ArrayScan VTI and software HCS Scan (Thermo-Fischer).
The factors EGF (Calbiochem), NGF2 (Sigma), IL-6 (ImmunoTools), IL-11
(Antigenix America, Inc.), and LIF (Chemicon) were added to the culture after
differentiation at concentrations of 0.8, 4, and 20 ng/ml. qRT-PCR was per-
formed as previously described (Tuckermann et al., 2007). Primer information
can be provided upon request. Statistical differences between the groups of
cultures (n = 3–6) were assessed by the Student’s t test.
CFU OBs
CFU OBs per leg were obtained by counting alizarin red-positive colonies of
2 3 106 bone marrow cells (excluding erythrocytes) plated per 6-well after
20 days under osteogenic conditions.
Coculture Experiments
Cocultures were established as previously described (David et al., 2005).
In brief, 0.5 3 106 fetal liver cells isolated from wild-type or GRnull embryos
were placed on top of wild-type, GRdim, or GRnull osteoblasts in the presence
of 10 nM colecalciferol with or without 1 mM Dex per 24-well. Primary osteo-
clasts were derived frombonemarrow of wild-type andGRdimmice in the pres-
ence of 50 ng/ml recombinant murine M-CSF and 30 ng/ml recombinant
murine RANKL (R&D Systems). TRAP-positive cells were stained after
7 days with the leukocyte acid phosphatase kit (Sigma) and counted per
24-well. Osteoclast apoptosis wasmeasured with ELISA (Cell Death Detection
ELISA, Roche). Resorption was assessed by seeding bone marrow cells on
osteocyte chambers in the presence of RANKL and M-CSF, with or without
Dex, and determination of resorption pits by von Kossa staining followed by
microscopy.
Immunoblotting
Primary dNRunx2Cre osteoblasts were treated with TNFa (Sigma) for 30 min.
Immunoblotting was performed with the nuclear (25 mg) and cytoplasmic
(40 mg) protein fractions using rabbit anti-RelA, rabbit anti-PolII, and goat
anti-b-actin (Santa Cruz).CRadiographic Analysis and Alizarin Red/Alcian Blue Staining
Whole skeletons were analyzed by contact radiography using a Faxitron X-ray
cabinet (Faxitron X-ray Corp., Wheeling, IL). For differential staining of bone,
E17.5 embryos were prepared according to the method of C. Arnott
(Kaufmann, 2003).
Histomorphometry
Parameters of static and dynamic histomorphometry were quantified on tolu-
idine blue-stained undecalcified proximal tibia and lumbar vertebral sections,
as described previously (Amling et al., 1999), using the Osteo-histomorphom-
etry system (Osteometrics, Atlanta, GA) (Parfitt et al., 1987). Osteocytes were
assessed at the cortical bone by OsteoMeasure software. To assess dynamic
histomorphometric indices, mice were given two injections of calcein, 9 and
2 days before dissection. Fluorochrome measurements for the determination
of the bone formation rate were performed on two nonconsecutive 12 mm thick
sections for each animal. Statistical differences between the groups (n = 5–6)
were assessed by the Student’s t test.
Osteoblast Proliferation and Apoptosis In Vivo
Mice were treated with prednisolone (12.5 mg/kg/d) for 1 day, and they got
pulsed with 10 mg/g body weight BrdU 4 hr before dissection. Decalcified
deparaffined femur sections were stained with the In Situ Cell Death Detection
Kit (Roche) for apoptosis and rat anti-BrdU (Abcam) following peroxidase-
coupled anti-rat IgG for proliferation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and two tables and can be
found with this article online at doi:10.1016/j.cmet.2010.05.005.
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